Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback